Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated Nov 6, 2023 (3 years ago)

Hydrocortisone 1% and Acetic Acid 2% Otic Solution USP (Hydrocortisone and Acetic Acid)

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Failed Impurities/Degradation Specifications:Out-of-Specification result for Hydrocortisone related impurity and slightly lower than the established level of the Hydrocortisone Assay obtained during stability testing.

Cause type: Impurity / degradation

An impurity or degradation product above its limit - other than nitrosamines. Unexpected substances in a batch can make it unsafe or less effective, even when the active ingredient is present. All impurity / degradation recalls.

What was recalled

Hydrocortisone 1% and Acetic Acid 2% Otic Solution USP, 10ml dropper bottle, RX Only, Mfd. by: Taro Pharmaceuticals Inc. Brampton, Ontario, Canada LGT 1C, Dist. by: Taro Pharmaceuticals U.S.A., Inc. Hawthorne, NY 10532. NDC 51672-3007-1

Affected NDC 51672-3007-01

Compare with the code on your package — it is the most precise check available.

Drug: Hydrocortisone

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Hydrocortisone and Acetic Acid
NDC 51672-3007
HYDROCORTISONE 10.4 mg/mL; ACETIC ACID 20.8 mg/mL Solution
Auricular (otic)
Sun Pharmaceutical Industries, Inc. Rx
Recalling firm
Taro Pharmaceuticals Inc.
NDC code
51672-3007-1
Origin
Canada
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0089-2024 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Hydrocortisone recalls

See all
Class II · Moderate risk

Med Pride

CGMP Deviations; deficiencies observed during FDA inspection

Ongoing cGMP deviation Dabur India Limited D-0640-2026
Class II · Moderate risk

Med Pride

CGMP Deviations; deficiencies observed during FDA inspection

Ongoing cGMP deviation Dabur India Limited D-0639-2026
Class III · Low risk

Skin Rehab

Subpotent Drug

Terminated Wrong potency / content Island Kinetics, Inc. d.b.a. CoValence Laboratories NDC 66915-531-04 D-0481-2026
Class III · Low risk

Remedy Gel

Subpotent Drug

Terminated Wrong potency / content Island Kinetics, Inc. d.b.a. CoValence Laboratories NDC 66915-531-12 D-0480-2026

Other recalls by Taro Pharmaceuticals Inc.

All 2023 recalls
Class II · Moderate risk

Desoximetasone Cream USP

Failed Stability Specifications: The subject lots exhibited OOS results for Homogeneity test (Moderate separation).

Terminated Stability / shelf life Taro Pharmaceuticals, Inc. NDC 51672-1271-7 D-0117-2017
Class II · Moderate risk

Desoximetasone Cream USP

Failed Stability Specifications: The subject lots exhibited OOS results for Homogeneity test (Moderate separation).

Terminated Stability / shelf life Taro Pharmaceuticals, Inc. NDC 51672-1270-7 D-0116-2017
Class III · Low risk

Topicort (desoximetasone)

Failed Impurities/Degradation Specifications: Out of specification results for impurities testing was obtained at the 6 and 9 month time points.

Terminated Impurity / degradation Taro Pharmaceuticals, Inc. D-1370-2015